

FIGURE 8. Sufficient barrier response protects differentiating ESCs from senescence, preventing the development of cancerous stem cells. *A*, protection of differentiating ESCs from senescence by treatment with anti-cancer drugs is shown. The experimental scheme is shown (*a*). Akt inhibitor IV and PARP inhibitor AZD2281 led to the reduction of surviving cells (*b*) and senescent cells (*c*). *B*, prevention of cancerous stem cell development in the presence of ROS is shown. Development of cancerous stem cells under NBS-med was inhibited in the absence of monoethioglycerol (MTG) as shown in the lower cell survival (*a*, compared with Fig. 6*A*), inhibition of senescence (*b*, P3 cells), and no piled-up sphere development (*b*, P6 + 10 days). The arrow indicates the sphere development in control conditions. Scale bars, 50 μ m.

DISCUSSION

Our results illustrated that ESCs differentiating under aberrant conditions, such as cultivation in NBS-med, are subject to carcinogenic stress, resulting in genomic instability, mutation in the *p53* locus, and the appearance of cancerous stem cells (Fig. 9). Although senescing MEFs subjected to carcinogenic

stress develop immortality without accompanying stemness and tumorigenicity (10), similar stresses in differentiating ESCs are associated with the development of malignancy. Thus, unlike differentiated cells, ESCs differentiating under environmental aberrancy suffer potentially from a risk of developing into cancerous stem cells upon spontaneous exposure to carcinogenic stress.

Differentiating Stem Cell Transformation




FIGURE 9. Model. In the process of ESC differentiation, cells subjected to environmental aberrancies are subjected to carcinogenic stress, resulting in the emergence of cancerous stem cells with genomic instability and mutations in p53 or Arf-p53 pathways.

Before their development into cancerous stem cells, ESCs differentiating in aberrant serum environments emulate cells in the initial stages of carcinogenesis, during which time they accumulate DNA lesions and exhibit barrier reactions, such as the induction of senescence and apoptosis. Genomic instability and mutations are also induced during the initial stages, contributing not only to the development of immortality but also to the acquisition of aberrant stemness characteristics that include the retention of stemness marker gene expression even under differentiation conditions. Thus, cancerous stem cells can propagate without losing stemness properties even in environments in which normal stem cells cannot maintain their undifferentiated status.

The development of CSCs is critical for carcinogenesis. In a manner analogous to the transformation of ESCs into cancerous stem cells, differentiating somatic stem cells can also be transformed into CSCs *in vivo* due to aberrant niche environments. This is supported by several documented observations: 1) age is a risk factor for defective niche function (23), 2) hematopoietic stem cells spontaneously accumulate endogenous DNA damage with age (49), and 3) disruption of the hematopoietic niche induces differentiation disorders in progenitor cells and secondary oncogenesis (22). In addition, humoral factors could be involved in the balance between progression and prevention of carcinogenic transformation; differentiating ESCs under NBS-med override the anti-cancer barrier and result in the development of cancerous stem cells, whereas those under FBS- and ABS-med are blocked. Importantly, this indicates that some conditions effectively induce anti-cancer barriers, as observed in FBS- and ABS-med, although this balance can also be altered by exogenous DNA damage. Thus, our results illustrate that normal stem cells can transform into CSCs during differentiation in aberrant environments and sug-

gest that the development of CSCs is prevented by effective induction of anti-cancer barrier responses, pointing to a potential target for cancer prevention.

REFERENCES

1. Wicha, M. S., Liu, S., and Dontu, G. (2006) Cancer stem cells. An old idea, a paradigm shift. *Cancer Res.* **66**, 1883–1890
2. Werbowetski-Ogilvie, T. E., and Bhatia, M. (2008) Pluripotent human stem cell lines. What we can learn about cancer initiation. *Trends Mol. Med.* **14**, 323–332
3. Chiba, T., Zheng, Y. W., Kita, K., Yokosuka, O., Saisho, H., Onodera, M., Miyoshi, H., Nakano, M., Zen, Y., Nakanuma, Y., Nakauchi, H., Iwama, A., and Taniguchi, H. (2007) Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. *Gastroenterology* **133**, 937–950
4. Liu, Y., Clem, B., Zuba-Surma, E. K., El-Naggar, S., Telang, S., Jenson, A. B., Wang, Y., Shao, H., Ratajczak, M. Z., Chesney, J., and Dean, D. C. (2009) Mouse fibroblasts lacking RB1 function form spheres and undergo reprogramming to a cancer stem cell phenotype. *Cell Stem Cell* **4**, 336–347
5. Bartkova, J., Horejsi, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldborg, P., Sehested, M., Nesland, J. M., Lukas, C., Ørntoft, T., Lukas, J., and Bartek, J. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. *Nature* **434**, 864–870
6. Gorgoulis, V. G., Vassiliou, L. V., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., Dittullo, R. A., Jr., Kastrinakis, N. G., Levy, B., Kletsas, D., Yoneta, A., Herlyn, M., Kittas, C., and Halazonetis, T. D. (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. *Nature* **434**, 907–913
7. Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L. V., Kolettas, E., Niforou, K., Zoumpourlis, V. C., Takaoka, M., Nakagawa, H., Tort, F., Fugger, K., Johansson, F., Sehested, M., Andersen, C. L., Dyrskjot, L., Ørntoft, T., Lukas, J., Kittas, C., Helleday, T., Halazonetis, T. D., Bartek, J., and Gorgoulis, V. G. (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. *Nature* **444**, 633–637
8. Ichijima, Y., Yoshioka, K., Yoshioka, Y., Shinohe, K., Fujimori, H., Unno, J., Takagi, M., Goto, H., Inagaki, M., Mizutani, S., and Teraoka, H. (2010) DNA lesions induced by replication stress trigger mitotic aberration and

- tetraploidy development. *PLoS One* **5**, e8821
9. Matheu, A., Maraver, A., Klatt, P., Flores, I., Garcia-Cao, I., Borrás, C., Flores, J. M., Viña, J., Blasco, M. A., and Serrano, M. (2007) Delayed ageing through damage protection by the *Arf/p53* pathway. *Nature* **448**, 375–379
 10. Sun, H., and Taneja, R. (2007) Analysis of transformation and tumorigenicity using mouse embryonic fibroblast cells. *Methods Mol. Biol.* **383**, 303–310
 11. Yang, Y. M., and Chang, J. W. (2008) Current status and issues in cancer stem cell study. *Cancer Invest.* **26**, 741–755
 12. Kim, J. H., Kim, S. H., Hahn, E. W., and Song, C. W. (1978) 5-Thio-D-glucose selectively potentiates hyperthermic killing of hypoxic tumor cells. *Science* **200**, 206–207
 13. Bunting, K. D. (2002) ABC transporters as phenotypic markers and functional regulators of stem cells. *Stem Cells* **20**, 11–20
 14. Seaberg, R. M., and van der Kooy, D. (2003) Stem and progenitor cells. The premature desertion of rigorous definitions. *Trends Neurosci.* **26**, 125–131
 15. Leahy, A., Xiong, J. W., Kuhnert, F., and Stuhlmann, H. (1999) Use of developmental marker genes to define temporal and spatial patterns of differentiation during embryoid body formation. *J. Exp. Zool.* **284**, 67–81
 16. Kondoh, H., Leonart, M. E., Gil, J., Wang, J., Degan, P., Peters, G., Martinez, D., Carnero, A., and Beach, D. (2005) Glycolytic enzymes can modulate cellular life span. *Cancer Res.* **65**, 177–185
 17. Dontu, G., El-Ashry, D., and Wicha, M. S. (2004) Breast cancer, stem/progenitor cells, and the estrogen receptor. *Trends Endocrinol. Metab.* **15**, 193–197
 18. Jones, D. L., and Wagers, A. J. (2008) No place like home. Anatomy and function of the stem cell niche. *Nat. Rev. Mol. Cell Biol.* **9**, 11–21
 19. Knoepfler, P. S. (2009) Deconstructing stem cell tumorigenicity. A roadmap to safe regenerative medicine. *Stem Cells* **27**, 1050–1056
 20. Morange, M. (2006) What history tells us VII. Twenty-five years ago. The production of mouse embryonic stem cells. *J. Biosci.* **31**, 537–541
 21. Wylie, C. (1999) Germ cells. *Cell* **96**, 165–174
 22. Raaijmakers, M. H., Mukherjee, S., Guo, S., Zhang, S., Kobayashi, T., Schoonmaker, J. A., Ebert, B. L., Al-Shahrour, F., Hasserjian, R. P., Scadden, E. O., Aung, Z., Matza, M., Merckenschlager, M., Lin, C., Rommens, J. M., and Scadden, D. T. (2010) Bone progenitor dysfunction induces myelodysplasia and secondary leukemia. *Nature* **464**, 852–857
 23. Smith, J. A., and Daniel, R. (2012) Stem cells and aging: a chicken-or-the-egg issue? *Aging Dis.* **3**, 260–268
 24. Fujimori, H., Asahina, K., Shimizu-Saito, K., Ikeda, R., Tanaka, Y., Teramoto, K., Morita, I., and Teraoka, H. (2008) Vascular endothelial growth factor promotes proliferation and function of hepatocyte-like cells in embryoid bodies formed from mouse embryonic stem cells. *J. Hepatol.* **48**, 962–973
 25. Marusyk, A., Wheeler, L. J., Mathews, C. K., and DeGregori, J. (2007) p53 mediates senescence-like arrest induced by chronic replication stress. *Mol. Cell Biol.* **27**, 5336–5351
 26. Fernandes, K. J., McKenzie, I. A., Mill, P., Smith, K. M., Akhavan, M., Barnabé-Heider, F., Biernaskie, J., Junek, A., Kobayashi, N. R., Toma, J. G., Kaplan, D. R., Labosky, P. A., Rafuse, V., Hui, C. C., and Miller, F. D. (2004) A dermal niche for multipotent adult skin-derived precursor cells. *Nat. Cell Biol.* **6**, 1082–1093
 27. Lee, B. Y., Han, J. A., Im, J. S., Morrone, A., Johung, K., Goodwin, E. C., Kleijer, W. J., DiMaio, D., and Hwang, E. S. (2006) Senescence-associated β -galactosidase is lysosomal β -galactosidase. *Aging Cell* **5**, 187–195
 28. Masaki, H., Nishida, T., Kitajima, S., Asahina, K., and Teraoka, H. (2007) Developmental pluripotency-associated 4 (DPPA4) localized in active chromatin inhibits mouse embryonic stem cell differentiation into a primitive ectoderm lineage. *J. Biol. Chem.* **282**, 33034–33042
 29. Nitou, M., Sugiyama, Y., Ishikawa, K., and Shiojiri, N. (2002) Purification of fetal mouse hepatoblasts by magnetic beads coated with monoclonal anti-e-cadherin antibodies and their *in vitro* culture. *Exp. Cell Res.* **279**, 330–343
 30. Lengauer, C., Kinzler, K. W., and Vogelstein, B. (1998) Genetic instabilities in human cancers. *Nature* **396**, 643–649
 31. Sherr, C. J., and McCormick, F. (2002) The RB and p53 pathways in cancer. *Cancer Cell* **2**, 103–112
 32. Zhang, P., Andrianakos, R., Yang, Y., Liu, C., and Lu, W. (2010) Kruppel-like factor 4 (Klf4) prevents embryonic stem (ES) cell differentiation by regulating Nanog gene expression. *J. Biol. Chem.* **285**, 9180–9189
 33. Jain, A. K., Allton, K., Iacovino, M., Mahen, E., Milczarek, R. J., Zwaka, T. P., Kyba, M., and Barton, M. C. (2012) p53 regulates cell cycle and microRNAs to promote differentiation of human embryonic stem cells. *PLoS Biol.* **10**, e1001268
 34. Ferrandina, G., Petrillo, M., Bonanno, G., and Scambia, G. (2009) Targeting CD133 antigen in cancer. *Expert Opin. Ther. Targets* **13**, 823–837
 35. Takahashi, K., and Yamanaka, S. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* **126**, 663–676
 36. Spierings, D. C., de Vries, E. G., Vellenga, E., and de Jong, S. (2003) The attractive Achilles heel of germ cell tumors. An inherent sensitivity to apoptosis-inducing stimuli. *J. Pathol.* **200**, 137–148
 37. Oh, S. K., and Choo, A. B. (2006) Human embryonic stem cells. Technological challenges toward therapy. *Clin. Exp. Pharmacol. Physiol.* **33**, 489–495
 38. Atsumi, Y., Fujimori, H., Fukuda, H., Inase, A., Shinohe, K., Yoshioka, Y., Shikanai, M., Ichijima, Y., Unno, J., Mizutani, S., Tsuchiya, N., Hippo, Y., Nakagama, H., Masutani, M., Teraoka, H., and Yoshioka, K. (2011) Onset of quiescence following p53-mediated down-regulation of H2AX in normal cells. *PLoS One* **6**, e23432
 39. Yoshioka, K., Atsumi, Y., Fukuda, H., Masutani, M., and Teraoka, H. (2012) The quiescent cellular state is *Arf/p53*-dependent and associated with H2AX down-regulation and genome stability. *Int. J. Mol. Sci.* **13**, 6492–6506
 40. Celeste, A., Difilippantonio, S., Difilippantonio, M. J., Fernandez-Capetillo, O., Pilch, D. R., Sedelnikova, O. A., Eckhaus, M., Ried, T., Bonner, W. M., and Nussenzweig, A. (2003) H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. *Cell* **114**, 371–383
 41. Woo, R. A., and Poon, R. Y. (2004) Activated oncogenes promote and cooperate with chromosomal instability for neoplastic transformation. *Genes Dev.* **18**, 1317–1330
 42. Deckbar, D., Birraux, J., Krempler, A., Tchouandong, L., Beucher, A., Walker, S., Stiff, T., Jeggo, P., and Löbrich, M. (2007) Chromosome breakage after G₂ checkpoint release. *J. Cell Biol.* **176**, 749–755
 43. Oh, S. J., Erb, H. H., Hobisch, A., Santer, F. R., and Culig, Z. (2012) Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. *Endocr. Relat. Cancer* **19**, 305–319
 44. Mitsiades, C. S., Mitsiades, N., and Koutsilieris, M. (2004) The Akt pathway. Molecular targets for anti-cancer drug development. *Curr. Cancer Drug Targets* **4**, 235–256
 45. Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., Ashworth, A., Carmichael, J., Kaye, S. B., Schellens, J. H., and de Bono, J. S. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N. Engl. J. Med.* **361**, 123–134
 46. Parrinello, S., Samper, E., Krtilica, A., Goldstein, J., Melov, S., and Campisi, J. (2003) Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. *Nat. Cell Biol.* **5**, 741–747
 47. Wiles, M. V., and Keller, G. (1991) Multiple hematopoietic lineages develop from embryonic stem (ES) cells in culture. *Development* **111**, 259–267
 48. Guachalla, L. M., and Rudolph, K. L. (2010) ROS induced DNA damage and checkpoint responses. Influences on aging? *Cell Cycle* **9**, 4058–4060
 49. Rossi, D. J., Bryder, D., Seita, J., Nussenzweig, A., Hoeijmakers, J., and Weissman, I. L. (2007) Deficiencies in DNA damage repair limit the function of hematopoietic stem cells with age. *Nature* **447**, 725–729

Therapeutic Effects of MicroRNA-582-5p and -3p on the Inhibition of Bladder Cancer Progression

Keita Uchino^{1,2}, Fumitaka Takeshita¹, Ryou-u Takahashi¹, Nobuyoshi Kosaka¹, Kae Fujiwara³, Haruna Naruoka³, Satoru Sonoke³, Junichi Yano³, Hideo Sasaki⁴, Shiari Nozawa⁴, Miki Yoshiike⁴, Kazuki Kitajima⁴, Tatsuya Chikaraishi⁴ and Takahiro Ochiya¹

¹Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan; ²Department of Biological Information, Tokyo Institute of Technology, Yokohama, Kanagawa, Japan; ³Discovery Research Laboratories in Tsukuba, Nippon Shinyaku Co., Ltd., Tsukuba, Ibaraki, Japan; ⁴Department of Urology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan

Many reports have indicated that the abnormal expression of microRNAs (miRNAs) is associated with the progression of disease and have identified miRNAs as attractive targets for therapeutic intervention. However, the bifunctional mechanisms of miRNA guide and passenger strands in RNA interference (RNAi) therapy have not yet been clarified. Here, we show that miRNA (miR)-582-5p and -3p, which are strongly decreased in high-grade bladder cancer clinical samples, regulate tumor progression *in vitro* and *in vivo*. Significantly, the overexpression of miR-582-5p or -3p reduced the proliferation and invasion of UM-UC-3 human bladder cancer cells. Furthermore, transurethral injections of synthetic miR-582 molecule suppressed tumor growth and metastasis in an animal model of bladder cancer. Most interestingly, our study revealed that both strands of miR-582-5p and -3p suppressed the expression of the same set of target genes such as *protein geranylgeranyltransferase type 1 beta subunit (PGGT1B)*, *leucine-rich repeat kinase 2 (LRRK2)* and *DIX domain containing 1 (DIXDC1)*. Knockdown of these genes using small interfering RNA (siRNA) resulted in the inhibition of cell growth and invasiveness of UM-UC-3. These findings uncover the unique regulatory pathway involving tumor suppression by both strands of a single miRNA that is a potential therapeutic target in the treatment of invasive bladder cancer.

Received 9 September 2012; accepted 26 November 2012; advance online publication 8 January 2013. doi:10.1038/mt.2012.269

INTRODUCTION

RNA interference (RNAi), a natural cellular process that regulates gene expression, is the most significant recent contribution to the field of cell biology.¹ Recently, RNAi-based therapies, which are harnessed to control the expression of pathogenic proteins, have been demonstrated in humans and have provided alternative powerful approaches to the traditional small molecule therapies. There has been an increase in the development of RNAi therapies for accessible tissues, such as the skin, retina, liver, and airways, due to their ability to be efficiently and safely delivered without unwanted side effects.²⁻⁴

Urinary bladder cancer remains one of the most costly cancers with regard to treatment and the monitoring of cytological changes, such as surveillance cystoscopy and periodic imaging.⁵ However, despite the existence of appropriate therapies, patients are continually under the threat of ongoing recurrence and progression to muscle.^{5,6} Therefore, the development of new treatment strategies to reduce the risk of recurrence and progression based on novel molecular networks is strongly desired. The facts described above provide an insight into an innovative approach that harnesses the power of the RNAi pathway; *i.e.*, the bladder maximizes the effect of RNAi therapy because of its accessibility and closed environment. Although some previous studies showed that the intravesical injection of small interfering RNA (siRNA) has potential as a treatment,^{7,8} whether an intravesical strategy can overcome the progression to muscle and metastasis in invasive bladder cancer remains unclear.

In cancer research, the copy number variation of DNA was a focus during the 1990s and the beginning of the 2000s as a result of the development of technologies such as array-based comparative genomic hybridization and microsatellite analysis,⁹⁻¹¹ because copy number gains or losses were believed to be specific markers for functional protein-coding genes. However, if protein-coding genes were not located in these aberrant regions, disease candidate regions were excluded from the functional analysis. On the other hand, recent studies found that microRNAs (miRNAs), which are key post-transcriptional regulators, are the main candidates for cancer-predisposing genes and that approximately half of the miRNAs are located at chromosomal regions that are genetically altered in cancers.¹²⁻¹⁴ Indeed, since their discovery, a widespread dysregulation of miRNAs caused by copy number variation is commonly observed in human cancers and has been shown to be involved in diverse physiological/pathological processes.¹⁵⁻¹⁹ In this study, we hypothesized that a novel tumor-suppressive miRNA or onco-miR can be identified more efficiently and more expeditiously by utilizing a vast amount of previously generated information about aberrant chromosomal regions related to bladder cancer.

Cytogenetic studies of bladder cancer have revealed a number of genetic aberrations.¹⁰ For discrimination of miRNAs which denote the abnormal expression in poorly prognostic patients

Correspondence: Takahiro Ochiya, Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan. E-mail: tochiya@ncc.go.jp

on bladder cancer, we focused on the copy number variation in UM-UC-3 cells which is one of the most invasive bladder cancer cell lines. It was reported that a number of genomic regions were deficient or amplified in that cell line.²⁰ Furthermore, in those genomic regions, 3p11-12, 4q33-34, and 5q12-13 were selected as analysis sets because the correlations between the copy number loss and bladder cancer progression in clinical samples had been reported by at least two groups.^{11,21-24} Although these regions include some miRNA genes, such as miR-1305, miR-1324, miR-578, miR-582-5p, and miR-582-3p, the modulation of the miRNA expression profiles and the exact functional mechanism are not thoroughly understood. In the present study, we report that miR-582-5p and miR-582-3p are concurrently downregulated in invasive bladder cancer, which is correlated with a copy number loss of chromosome 5q12. These significant reductions of miR-582-5p and -3p were also observed in clinical samples and strongly correlated with tumor grade. Furthermore, the restorations of miR-582-5p or -3p strongly inhibit cell proliferation and invasion. In the lung metastasis mouse model of human bladder cancer, involving orthotopic transplantation, the injection of the miR-582/cationic liposome complex prevented tumor growth and lung metastasis. This demonstration is the first, to our knowledge, to show inhibition of tumor metastasis in an orthotopic model by intravesical miRNA injection.

Two mature miRNAs can be generated from the same stem-loop pre-miRNA.²⁵ These 5p and 3p miRNAs, although excised from a single primary transcript, have different sequences and therefore target different mRNAs. Despite nearly a decade of studies on miRNA, the effect of strand-specific mature miRNAs has not yet been fully understood. In the present study, we also provide evidence that the expression of *protein geranylgeranyltransferase type I beta subunit (PGGT1B)*, *leucine-rich repeat kinase 2 (LRRK2)*, and *DIX domain containing 1 (DIXDC1)*, which are involved in the cell growth and the invasiveness, is bifunctionally regulated by the effects of both strands of miR-582-5p and -3p. These findings suggest that a novel pathway involving miR-582 and cancer-related genes has the potential to be a critical target for the therapeutic treatment of invasive bladder cancer.

RESULTS

Downregulation of miR-582-5p and -3p in bladder cancer cell lines

To identify miRNAs downregulated in bladder cancer cell lines, we performed quantitative reverse transcription-PCR (qRT-PCR) for miR-1305, miR-1324, miR-578, and miR-582-5p and -3p, which are located in aberrant genomic regions correlated with tumor progression (Supplementary Tables S1 and S2). The results showed no downregulation of miR-1305 in bladder cancer cells (Supplementary Figure S1a), and the expression of miR-1324 and miR-578 was not detected in either bladder cancer cell lines or normal bladder tissue RNA, but we found that miR-582-5p and -3p are strongly downregulated in invasive bladder cancer cell lines (UM-UC-3, 5637, MBT2, J82, TCCSUP) (Figure 1a). Furthermore, the copy number of chromosome 5q12, in which the miR-582 gene is located, was lower in UM-UC-3 cells than in HT1376 cells (Figure 1b). HT1376 cells were reported to not have a loss in 5q12.²⁴ However, the degree of downregulation of miR-582 expression in




Figure 1 Expression level of miR-582-5p and -3p in human bladder cancer cell lines. (a) Expression level of miR-582-5p and -3p in human bladder cancer cell lines and a mouse bladder cancer cell line (MBT2). The relative expression of miR-582 for each of the cell lines was calculated compared with the level in normal bladder tissue RNA. (b) Copy number change of the miR-582 loci on chromosome 5q12. The HT1376 cell line was used as the control for this experiment.

UM-UC-3 cells seems too strong compared with the reduction of the copy number. This means that a remarkable reduction of miR-582-5p and -3p expression might be invoked by a combination of copy number loss and other factors. To identify whether the expression of these mature miRNAs are reduced in a transcriptional or biogenic process, we assessed the expression levels of pri-miR-582 and *phosphodiesterase 4D (PDE4D)* because miR-582 is located in the intronic region of *PDE4D*. The expression levels of pri-miR-582 and *PDE4D* are strongly reduced in UM-UC-3 and 5637 cells (Supplementary Figure S1b,c). These results indicate that the expression of miR-582-5p and -3p is reduced by the combination of copy number loss and transcriptional attenuation.

Downregulation of miR-582-5p and -3p in clinical samples

We examined the expression levels of miR-582-5p and -3p in laser capture-microdissected bladder cancer tissue regions ($n = 53$) and matched adjacent normal regions ($n = 31$) derived from 28 patients (Supplementary Table S3). Relative to normal regions, the tumor regions showed markedly lower miR-582-5p and -3p expression levels (Figure 2a). In particular, we found that these levels tend to decrease more remarkably in invasive tumors (tumor stage $\geq pT1$) than in superficial tumors (tumor stage pTis and pTa) (Figure 2b) (miR-582-5p: superficial tumor $P = 0.006$, invasive tumor $P = 0.003$; miR-582-3p: superficial tumor $P = 0.035$, invasive tumor $P < 0.001$). Furthermore, a strong correlation was




Figure 2 Expression level of miR-582-5p and -3p in bladder cancer tissue samples. (a) Expression of miR-582-5p and -3p in clinical samples, which show the downregulation in the tumor region compared with the adjacent normal tissues (tumor: $n = 53$, normal bladder: $n = 31$). The boxes and whiskers range from 25% to 75% and from 10% to 90%, respectively. * $P < 0.01$ versus normal bladder. (b) Comparison with the tumor stages in carcinoma cells paired with normal bladder tissue (superficial tumor: $n = 18$, invasive tumor: $n = 10$). (c) Comparison with the tumor grades in carcinoma cells paired with normal bladder tissue. All values for the miRNA expression levels were normalized to hsa-miR-103 as an internal control (Grade I: $n = 9$, Grade II: $n = 12$, Grade III: $n = 7$).

Table 1 Downregulation in clinical samples (fold change >2.5)

	Superficial (pTis, pTa)	Invasive (\geq pT1)	Grade I	Grade II	Grade III
miR-582-5p (%)	7/18 (38.9)	9/10 (90)	3/9 (33.3)	6/12 (50)	7/7 (100)
miR-582-3p (%)	9/18 (50)	7/10 (70)	2/9 (22.2)	8/12 (66.7)	6/7 (85.7)

also observed between tumor grade and the downregulation of miR-582-5p and -3p (Figure 2c) (miR-582-5p: Grade I $P = 0.042$, Grade II $P = 0.028$, Grade III $P = 0.006$; miR-582-3p: Grade I $P = 0.206$, Grade II $P = 0.270$, Grade III $P = 0.046$). In addition to this, the ratio of samples showing strong downregulation greater than a 2.5-fold change increased as the tumor stage and grade advanced (Table 1). These data suggested that miR-582-5p and -3p levels vary with the malignancy potential and are potential therapeutic markers in the treatment of invasive bladder cancer.

Effect of miR-582-5p and -3p on cell proliferation and invasive ability

To investigate the functional role of miR-582-5p and -3p in bladder cancer, we performed a cell proliferation assay and a cell invasion assay. UM-UC-3, J82, and TCCSUP cells were transfected transiently with miR-582, miR-582-5p, miR-582-3p, and negative control (NC) siRNA. miR-582 is synthesized to mimic endogenous mature miR-582, whereas miR-582-5p and -3p are

designed to match perfectly and complementarily to each strand, similar to siRNA. Three days after transfection, the cell viability was decreased from 30% to 80% in the miR-582-, miR-582-5p-, or miR-582-3p-transfected cells compared with the NC cells (Figure 3a). The matrigel invasion assay showed that the cell invasion ability was significantly ($>70\%$) decreased in miR-582-, miR-582-5p-, or miR-582-3p-transfected UM-UC-3, J82, and TCCSUP cells (Figure 3b,c). These results suggest that the cell proliferation and invasive abilities of bladder cancer cells were severely affected only by either strand of miR-582-5p or miR-582-3p. In addition, a reduction of invasiveness was observed in 5637 cells, although T24 cells did not show a significant response to miR-582 in the cell proliferation and cell invasion assays (Supplementary Figure S2a,b). The expression and functional data suggest that the tumor-suppressive role of miR-582 is correlated with the reduction of its expression level in bladder cancer cells.

To ensure that the functions of miR-582-5p and -3p are not at a supraphysiological level, we repeated these experiments using a stable miRNA vector that synthesizes mature miRNAs by biological processing. UM-UC-3 cells were transduced with a lentiviral construct stably expressing precursor miR-582, and the expression level was examined (Supplementary Figure S3a). Furthermore, the functional analysis revealed that UM-UC-3 cells stably expressing miR-582 (UM-UC-3-miR-582) show a significant repression of cell proliferation and invasion (Supplementary Figure S3b,c).




Figure 3 Function of miR-582 in human bladder cancer *in vitro* and *in vivo*. **(a)** Effect of miR-582 on cell proliferation of UM-UC-3, J82 and TCCSUP. The proliferation values were normalized to the values from cells treated with NC ($n = 6$). $*P < 0.01$ versus NC. **(b,c)** Effect on cell invasion. The invasive values were normalized to the values from cells treated with NC ($n = 4$). $*P < 0.01$ versus NC (scale bar: 100 μm). **(d)** Inhibition of tumor growth by miR-582 treatment in a murine orthotopic xenograft model of human bladder cancer. The mice were injected with 5×10^6 UM-UC-3-luc cells into the bladder on day 0. miR-582 and miR-582-scramble (10 μg) with cationic liposomes in a 70 μl volume were injected into the bladder on days 4, 6, 8, 11, 13, and 15 after tumor injection. **(e,f)** The growth curves of the orthotopically transplanted UM-UC-3-luc cells were measured by IVIS. Filled diamonds: treatment with miR-582-scramble; Open squares: treatment with miR-582 (scramble: $n = 8$, miR-582: $n = 10$). **(g)** Inhibition of lung metastasis by miR-582 treatment in an orthotopic bladder cancer mouse model. The images were obtained by IVIS on day 26 after transplantation. **(h)** Quantitation of bioluminescence emitted from the whole lungs of mice on day 26. The boxes and whiskers range from 25% to 75% and from 10% to 90%, respectively. $*P < 0.05$ versus scramble. NC, negative control.

By contrast, as shown in a loss-of-function assay using the locked nucleic acid–modified anti-miRNA oligonucleotides against each strand of miR-582-5p and -3p, cell proliferation and invasion are promoted in UM-UC-3-miR-582 cells (Supplementary Figure S3d,e). These results indicate that the presence of either miR-582-5p or -3p was sufficient to suppress tumor growth and invasiveness.

Inhibition of tumor growth and metastasis *in vivo* with miR-582 treatment

To assess the therapeutic potential of miR-582, we used an orthotopic bladder cancer mouse model featuring UM-UC-3-luc cells, which have the capacity to form tumors in the bladder and spread to the lungs of mice. The cationic liposome, LIC-101 (Nippon Shinyaku, Tsukuba, Japan), was used to deliver miR-582 into the tumor cells in the mouse bladder. The miR-582/LIC-101 or miR-582-scramble/LIC-101 complexes were injected transurethrally into

the bladder at 5, 7, 9, 11, 13, and 15 days after tumor transplantation (Figure 3d). These results demonstrated that miR-582 successfully suppressed tumor growth *in vivo*; in particular, we found that miR-582 provided a greater than fourfold reduction of the tumor growth in the fourth week (Figure 3e). Furthermore, there was a significant difference in fold changes relative to the photon counts in the first week (miR-582 = $2,253.5 \pm 851.7$, scramble = 187.1 ± 108.9 , $P = 0.042$) (Figure 3f). At the end of the experiment, 4 weeks after transplantation, the mice treated with miR-582-scramble showed a more frequent presence of tumors in the lung (5 of 8; 63%) than in the miR-582 group (1 of 10; 10%) (Figure 3g). Moreover, there was a significant difference between the two groups regarding the luminescence of the lung (Figure 3h). These results indicated that the intravesical administration of the miR-582/LIC101 complex could be a novel therapeutic strategy for the inhibition of tumor progression and metastasis in bladder cancer.




Figure 4 Identification of *PGGT1B*, *LRRK2*, *DIXDC1*, *RAB27A*, and *KCNC1* as miR-582-5p and -3p target genes. Target validations of *KCNC1*, *PGGT1B*, *LRRK2*, *RAB27A*, and *DIXDC1* were confirmed by qRT-PCR, western blot analysis, and cell proliferation, cell invasion, and luciferase reporter assays. **(a)** qRT-PCR was performed in UM-UC-3 cells at 24 hours after transfection with miR-582. The relative expressions of the target mRNAs were calculated compared with the level in NC ($n = 3$). **(b)** Western blot analysis was performed in UM-UC-3 cells at 48 hours after transfection. Actin was used as the loading control. **(c)** Effect of target siRNAs on the proliferation of UM-UC-3. The proliferation values were normalized to values from cells treated with NC ($n = 6$). **(d)** Effect of target siRNAs on the invasion of UM-UC-3. The invasive values were normalized to the values from cells treated with NC ($n = 3$). **(e)** Each luciferase reporter construct containing a target 3'UTR was cotransfected with miR-582, miR-582-5p or -3p, or NC into UM-UC-3 cells ($n = 6$). * $P < 0.05$ versus NC. NC, negative control; qRT-PCR, quantitative reverse transcription-PCR.

Table 2 Summary of the number of target sites for miR-582-5p and -3p

Target 3'UTR	Number of predicted binding site		
	miR-582-5p	miR-582-3p	
KCNC1	Site-1	1	0
	Site-2	1	1
PGGT1B		5	1
LRRK2		1	2
RAB27A		4	0
DIXDC1	Site-1	2	2
	Site-2	0	1

Identification of miR-582-5p and -3p target genes

To identify miR-582-5p and -3p target genes, hemagglutinin (HA)-tagged Ago2-immunoprecipitation (Ago2-IP) and mRNA array analysis were performed. The UM-UC-3-Ago2 cells stably expressing HA-tagged-Ago2 were transfected with miR-582, and the Ago2-RNA complexes were precipitated with the anti-HA antibody, which was followed by the microarray analysis. The total RNA from UM-UC-3-Ago2 cells transiently transfected with miR-582 and from UM-UC-3-miR-582 cells was also analyzed (**Supplementary Figure S4a**). As a result, 259 genes were identified as candidates for directly targeted genes, and 1,559 genes were identified as candidates for indirectly targeted genes that are downstream of the direct targets (**Supplementary Tables S4 and S5**). In addition to these experimental approaches, we used two

target prediction algorithms (TargetScan: <http://www.targetscan.org>, miRanda: <http://www.microrna.org>) as *in silico* approaches. After calculating the fold change and conducting an overlapping prediction analysis, we validated the identified 42 genes by qRT-PCR (**Supplementary Figure S4b**), western blotting analysis, and cell proliferation, cell invasion, and 3'UTR reporter assays. The results of the qRT-PCR and western blotting analyses demonstrated that the expression levels of the mRNA and protein of five genes—*potassium voltage-gated channel subfamily C member 1 (KCNC1)*, *PGGT1B*, *LRRK2*, *DIXDC1*, and *ras-related GTP-binding protein (RAB27A)*—were more downregulated by transfection with miR-582, or miR-582-5p, or -3p than the NC siRNA-treated cells (**Figure 4a,b**). Furthermore, silencing of these target genes by siRNAs showed a remarkable inhibition of cell proliferation and cell invasion in UM-UC-3 cells (**Figure 4c,d**). These five genes have several putative binding sites for miR-582-5p or -3p in their 3'UTRs (**Table 2** and **Supplementary Table S6**). Indeed, the expression of each luciferase reporter gene fused with the 3'UTR of *PGGT1B*, *LRRK2* and *DIXDC1* was suppressed by transfection with miR-582, miR-582-5p, or -3p (**Figure 4e**). Conversely, the expression of that of *RAB27A* was suppressed by miR-582 and miR-582-5p. There was no significant difference in the expression of that of *KCNC1*. These results indicated that miR-582-5p and -3p regulate the expression of *PGGT1B*, *LRRK2*, and *DIXDC1* by binding their 3'UTRs. One strand, miR-582-5p, can directly bind 3'UTR of *RAB27A* and regulate the expression. In contrast, the downregulation of *KCNC1* by transfection with miR-582-5p and -3p is not a direct consequence of miR-582.




Figure 5 Representative examples of immunohistochemical expression of different gene products in human bladder cancer. Target gene localization in clinical samples by IHC. Left panel: representative normal bladder biopsy (scale bar: 100 μ m); Right panel: representative bladder cancer with strong staining observed. A black arrow shows the fold change of the downregulation of miR-582-5p or -3p in tumor tissue compared with the adjacent normal tissues (single black arrow: fold change <math>< 2.0</math>, double black arrows: fold change = \times 20. IHC, immunohistochemistry.

In addition, we performed an immunohistochemical analysis to observe the expression of these target genes in clinical samples of human bladder cancer. Strong nuclear or cytoplasmic staining was observed in the tumors but not in the adjacent normal bladder tissues (Figure 5). Furthermore, there was a positive correlation between the expression levels of target genes and tumor stage or grade of bladder cancer, and miR-582 was downregulated, whereas, in the low-stage or -grade bladder cancer, a high expression of target genes was not notably observed. These results suggest that the expressions of these cancer-related genes are a clinically relevant biological process,

and the levels of the expressions are correlated with malignancy potential in bladder cancer.

DISCUSSION

Genetic changes potentially affect all medical conditions and are associated with thousands of diseases.²⁶ The amplification of oncogenes or deletion of tumor-suppressor genes can broadly influence tumor initiation and progression.^{21,24} Although many previous reports have indicated the correlation between region-specific gain or loss of DNA and tumor progression in bladder cancer, it has not yet been fully elucidated as to which genes, including

noncoding RNAs, are responsible for these different observations. In particular, the losses of chromosomes 3p11-12, 4q32-34, and 5q12-13 loci were reported to be associated with clinicopathological factors in bladder cancer.^{11,21-24} Here, we provided evidence on the relationship between the copy number loss of 5q12 and tumor progression via post-transcriptional regulation by miRNA. We demonstrated a novel pathway of paired tumor-suppressive miRNAs, miR-582-5p and -3p located on 5q12, which are specifically attenuated in invasive bladder cancer cells by copy number loss. Furthermore, the expression levels of miR-582-5p and -3p were remarkably lower in bladder cancer tissues and correlated with the tumor grade. These clear correlations suggest an important role for miR-582 on bladder cancer progression.

Despite these considerable dysregulations, there are no reports concerning the expression profiling and functional role of miR-582 in bladder cancer. Thus, focusing on miR-582 as a new candidate tumor-suppressive miRNA in bladder cancer is natural. As expected, the restoration of miR-582-5p or -3p expression inhibited the cell proliferation and invasion in UM-UC-3 cells. Generally, most miRNA duplexes can be functionally asymmetric due to unequal election for assembly into RISC and distinct sequence features. Although previous reports showed that miR199a-5p and -3p or miR-297b-5p and -3p target same mRNAs,^{27,28} for this reason, it is extremely rare that each strand of mature miRNA, 5p and 3p, has an identical property in the same physiological/pathological processes. The present experiment indicated that both strands of miR-582-5p and -3p have tumor-suppressive activities based on their sequences.

The number of RNAi-based preclinical and clinical trials has grown over the past several years, and these trials provide opportunities for success.²⁴ These studies were conducted mainly in specific organs, such as eyes, dermis, and lung, which were relatively accessible by topical or local administration. Thus, accessibility is a key requirement for successful RNAi *in vivo* to be delivered tissue specifically or cell specifically. Here, in a closed environment of the bladder, the intravesical injection of miRNA is expected to offer high specificity to a tissue and noninvasive administration. Indeed, a previous study showed that the low-toxic cationic liposome, LIC-101, and the dsRNA complex could be successfully delivered into the bladder tissue and were able to affect tumor growth.⁷ However, whether transurethral injection is effective against a severe problem, such as invasion into the muscle and metastasis, remains unknown. In this study, we were successful at providing evidence for this procedure by showing that the instillation of the synthetic miR-582/LIC-101 complex inhibited both lung metastasis and tumor growth. For the first time, our findings have provided a new insight into the availability of a bladder cancer lung metastasis model mouse in RNAi therapeutic trials.

miRNAs are known to have the potential to target thousands of different mRNAs, and each mRNA is also targeted by multiple miRNAs.^{29,30} Although target prediction algorithms (TargetScan, miRanda) such as *in silico* approaches based on prior experimental studies can help to predict miRNA-binding targets, computational algorithms are imperfect and insufficient to identify some essential or novel target genes. Hence, in addition to *in silico* analysis, as an optimized and high-throughput biochemical assay, we evaluated the use of Ago2-IP.³¹⁻³³ The validation studies revealed that miR-582-5p and -3p have a tumor-suppressive function by both the

inhibition of translation and the degradation of *KCNK1*, *PGGT1B*, *LRRK2*, *DIXDC1*, and *RAB27A*. Although miR-582 did not regulate *KCNK1* expression directly, it is very interesting that *KCNK1* has a novel remarkable function in cell proliferation (Figure 4c), because it usually works as a potassium ion transporter. *PGGT1B* is involved in the geranylgeranylation of RhoA and the activation of *MMP-9*, resulting in the disruption of F-actin organization and the progression of cell motility, invasion, and metastasis.^{34,35} The kinase domain of *LRRK2* is homologous to B-RAF kinase, which is well known to drive malignant melanoma. Furthermore, *LRRK2* is related to the direct phosphorylation of *Akt1*, resulting in cell survival and the prevention of apoptosis.^{36,37} *DIXDC1*, which works as a receptor of the Wnt signaling pathway, is related to the upregulation of *CyclinD1* and the downregulation of p21. The siRNA knockdown of *DIXDC1* was reported to cause G1/S phase arrest in colon cancer.^{38,39} *RAB27A*, a member of the RAS oncogene family, is well known to be a driver of melanoma and breast cancer, promoting cell proliferation, invasion, and metastasis potential.^{40,41} It is also involved in the regulation of membrane trafficking and exosome formation.⁴² This study carries considerable potential to provide novel insights into the pathogenic mechanisms of exosomes regulated by miR-582-5p in invasive bladder cancer.

In conclusion, this study provides two novel findings in bladder cancer. First, we presented evidence of a unique regulatory pathway involving a couple of tumor-suppressive miRNAs, miR-582-5p and -3p, that are downregulated in invasive bladder cancer. The significant dysregulation of the miR-582 network may contribute to the progression of other invasive cancers, and we are actively investigating this hypothesis. Second, an *in vivo* experiment showed the possibility of the application to a therapeutic target against the continued threat of progression to muscle invasion and metastasis. Importantly, our findings provide an insight into the unique regulatory pathway, which has a coordinated role between miRNA-5p and -3p. These novel findings also provide a potential value of an extreme contribution to the development of the cancer therapy as a prominent class of RNAi therapy.

MATERIALS AND METHODS

Cell culture. The human bladder cancer cell lines UM-UC-3, 5637, J82, TCCSUP, T24, HT1376, and RT4 and the mouse bladder cancer cell line MBT2 were obtained from the American Type Culture Collection (Manassas, VA). The UM-UC-3, J82, TCCSUP, T24, and MBT2 cells were cultured in Modified Eagle's Medium (Sigma-Aldrich, St Louis, MO) containing 10% heat-inactivated fetal bovine serum (Invitrogen, Carlsbad, CA) and an antibiotic-antimycotic (Invitrogen) at 37°C in 5% CO₂. The 5637 cells were cultured in RPMI (Invitrogen) containing 10% heat-inactivated fetal bovine serum and an antibiotic-antimycotic at 37°C in 5% CO₂. The T24 and RT4 cells were cultured in McCoy's 5A (Sigma-Aldrich) containing 10% heat-inactivated fetal bovine serum and an antibiotic-antimycotic at 37°C in 5% CO₂.

Patients and human samples. All human bladder tissue samples were derived from the resected bladders of 29 patients who underwent transurethral resection or radical cystectomy at the Department of Urology, St. Marianna University between 2009 and 2011. The samples of tumor and normal epithelium were fixed in formalin, embedded in paraffin, and sectioned for use in microscopic analysis and laser capture microdissection. All materials were obtained with written informed consent, and the study protocols were approved by the Institutional Review Board at the National Cancer Center Research Institute and St. Marianna University.